Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3954068 in Early Symptomatic Alzheimer's Disease
NCT06297590Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2024
- Primary completion
- Jul 2028
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of LY3954068 in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Adverse Events at 76 weeks. Started Aug 2024; status: recruiting.
02
Drugs
LY3954068
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06297590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297590.